Prostate cancer—highlights from American Society of Clinical Oncology virtual meeting 2020
-
Published:2022-07
Issue:3
Volume:9
Page:282-286
-
ISSN:2214-3882
-
Container-title:Asian Journal of Urology
-
language:en
-
Short-container-title:Asian Journal of Urology
Author:
Naqos Nora,Kaikani Wafaa
Reference14 articles.
1. Oral relugolix for androgen deprivation therapy in advanced prostate cancer;Shore;N Engl J Med,2020
2. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC);Small;J Clin Oncol,2020
3. Darolutamide in nonmetastatic, castration-resistant prostate cancer;Fizazi;N Engl J Med,2019
4. Final overall survival (OS) from PROSPER: a phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC);Sternberg;J Clin Oncol,2020
5. Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): matching-adjusted indirect comparisons;Jiang;J Clin Oncol,2020